In this study, we demonstrate that novel-miR-7-enriched hepatic sEV directly targets the lysosomal-associated membrane protein 1 (LAMP1)/Cathepsin B/NLRP3 inflammasome axis and induces microvascular endothelial hyperpermeability during NAFLD. Here, NLRP3 is linked to metabolic dysfunction-associated steatotic liver disease.